Horning Sandra J
Division of Oncology, Stanford University School of Medicine, Palo Alto, Ca 94304, USA.
Semin Oncol. 2003 Dec;30(6 Suppl 17):29-34. doi: 10.1053/j.seminoncol.2003.10.006.
Rituximab has become a staple in the management of B-cell non-Hodgkin's lymphoma, but it has limited activity as a single agent, with responses in about half of patients with recurrent follicular and low-grade lymphoma. Radioimmunotherapy (RIT) may surmount inherent or acquired antibody resistance by targeting a radionuclide to tumor cells. This strategy is particularly appealing for B-cell lymphoma because CD20 affords an outstanding target and lymphomas are inherently radiosensitive. The efficacy and safety of RIT have been established in the treatment of relapsed or refractory indolent non-Hodgkin's lymphoma, and yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) was the first RIT agent to be approved by the US Food and Drug Administration. This supplement to Seminars in Oncology seeks to present hematologists and medical oncologists with the most recent developments in RIT with (90)Y ibritumomab tiuxetan for non-Hodgkin's lymphoma, to clarify the role of the medical oncologist in the administration of the ibritumomab tiuxetan regimen, to indicate how and when RIT with (90)Y ibritumomab tiuxetan may most successfully be integrated into the continuum of treatment for patients with B-cell lymphoma, and to describe ongoing clinical trials with (90)Y ibritumomab tiuxetan in B-cell lymphomas.
利妥昔单抗已成为B细胞非霍奇金淋巴瘤治疗的主要药物，但作为单一药物其活性有限，约半数复发滤泡性和低度淋巴瘤患者有反应。放射免疫疗法（RIT）可通过将放射性核素靶向肿瘤细胞来克服固有或获得性抗体耐药性。该策略对B细胞淋巴瘤特别有吸引力，因为CD20提供了一个出色的靶点，且淋巴瘤本质上对放疗敏感。RIT在复发或难治性惰性非霍奇金淋巴瘤治疗中的疗效和安全性已得到证实，钇90 替伊莫单抗（泽瓦林；百健艾迪公司，马萨诸塞州剑桥）是首个获美国食品药品监督管理局批准的RIT药物。《肿瘤学研讨会》的这份增刊旨在向血液科医生和医学肿瘤学家介绍钇90 替伊莫单抗治疗非霍奇金淋巴瘤的RIT最新进展，阐明医学肿瘤学家在替伊莫单抗治疗方案管理中的作用，指出钇90 替伊莫单抗RIT如何以及何时最成功地融入B细胞淋巴瘤患者的连续治疗中，并描述钇90 替伊莫单抗在B细胞淋巴瘤中的正在进行的临床试验。
